Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism

Turner, S.; Francis, Ben; Vijverberg, Susanne; Pino-Yanes, Maria; Maitland-van der Zee, Anke H.; Basu, Kaninika

Published in:
Journal of Allergy and Clinical Immunology

DOI:
10.1016/j.jaci.2015.10.045

Publication date:
2016

Document Version
Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Childhood asthma exacerbations and the Arg-16 beta2 receptor polymorphism: a meta-analysis stratified by treatment

Steve Turner MD, Ben Francis PhD, Susanne Vijverberg PhD, Maria Pino-Yanes PhD, Anke H Maitland-van der Zee PhD, Kaninika Basu MD, Lauren Bignell MBBS, Somnath Mukhopadhyay MD, Roger Tavendale PhD, Colin Palmer PhD, Daniel Hawcutt PhD, Munir Pirmohamed PhD, Esteban G Burchard MD MPH and Brian Lipworth MD on behalf of the Pharmacogenomics in Childhood Asthma consortium.

1 Child Health, University of Aberdeen
2 Department of Biostatistics, University of Liverpool, Liverpool
3 Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht
4 CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
5 Research Unit, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, Spain
6 Academic Department of Paediatrics, Royal Alexandra Children’s Hospital, Brighton and Sussex Medical School, Brighton, United Kingdom.
7 Population Pharmacogenetics Group, University of Dundee
8 Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool
9 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool
10 Department of Bioengineering and Therapeutic Sciences and Medicine, University of California, San Francisco, USA
11 Center for Genes, Environment and Health, University of California, San Francisco, USA
12 Asthma and allergy Research Group, University of Dundee
Contact details: Dr S Turner, Child Health, Royal Aberdeen Children’s Hospital, Aberdeen, AB25 2ZG tel +44 1224 438475, fax +44 1224 438469, s.w.turner@abdn.ac.uk

Funding sources. There were no funds for the present analysis and the individual cohorts were funded as follows:

BREATHE was funded by Scottish Enterprise Tayside, the Gannochy Trust, the Perth and Kinross City Council and Brighton and Sussex Medical School.

GALA II. The contribution from GALA II to this work was supported by grants from National Institutes of Health to E.G.B.: the National Heart, Lung and Blood Institute (HL088133, HL078885, HL004464, HL104608 and HL117004); the National Institute of Environmental Health Sciences (ES015794); the National Institute on Minority Health and Health Disparities (MD006902); the National Institute of General Medical Sciences (GM007546). E.G.B was also funded by the American Asthma Foundation, the RWJF Amos Medical Faculty Development Award, the Sandler Foundation and the Flight Attendant Medical Research Institute. MPY was supported by a postdoctoral fellowship from Fundacion Ramon Areces (www.fundacionareces.es).

PACMAN was funded by a strategic alliance between GSK and Utrecht Institute for Pharmaceutical Sciences.

PAGES was funded by the Chief Scientist Officer for Scotland.

PASS was funded by the UK department of health through the "NHS Chair of Pharmacogenomics

None of the authors has any financial relationship with a biotechnology and/or pharmaceutical manufacturer that has an interest in the subject matter or materials discussed in the submitted manuscript.

Running head: ADRB2 and childhood asthma exacerbations

Word count for main body of manuscript: 2793
ABSTRACT

Background. The Gly-to-Arg substitution at the 16 position (rs1042713) in the beta 2 adrenoceptor (ADRB2) gene is associated with enhanced down-regulation and uncoupling of beta-2 receptors.

Objectives. To undertake a meta-analysis to test the hypothesis that there is an interaction between the A allele of rs1042713 (Arg16 amino acid) and long acting beta agonist (LABA) exposure for asthma exacerbations in children.

Methods. Children with diagnosed asthma were recruited in five populations (BREATHE, GALA II, PACMAN, PAGES and PASS). A history of recent exacerbation and asthma treatment were determined from questionnaire data. DNA was extracted and the Gly16Arg genotype determined.

Results. Data from 4226 children of white Northern European and Latino origin were analysed and the odds ratio for exacerbation increased by 1.52 [1.17, 1.99] p=0.0021 for each copy of the A allele among the 637 children treated with inhaled corticosteroids (ICS) plus LABA but not for treatment with ICS alone (n=1758), nor ICS plus leukotriene receptor antagonist (LTRA, n=354) or ICS plus LABA plus LTRA (n=569).

Conclusions. The use of LABA as “add-on controller”, but not LTRA, is associated with increased risk of asthma exacerbations in children carrying one or two A alleles at rs1042713. Prospective genotype stratified clinical trials are now required to explore the potential role of rs1042713 genotyping for personalised asthma therapy in children.

Key words: Adrenergic receptors; Asthma; Child; Disease exacerbation; Therapeutics.
Clinical trials are required to determine whether treatment stratified by rs1042713 will reduce asthma exacerbation risk in children with one or two A alleles.
CAPSULE SUMMARY

This meta-analysis finds increased asthma exacerbation risk for children who carry ≥ 1 A allele of rs1042713, but only in the context of treatment with inhaled corticosteroids and long acting beta agonist.
ABBREVIATIONS

ADRB2 Beta 2 Adrenoceptor
LABA Long Acting Beta Agonists
LTRA Leukotriene Receptor Antagonist
ICS Inhaled Corticosteroids
MAF Minor Allele Frequency
PAGES Paediatric Asthma Gene Environment Study
PASS Pharmaco genetics of Adrenal Suppression with inhaled Steroid study
SABA Short Acting Beta Agonists
SNP Single Nucleotide Polymorphism
INTRODUCTION

Asthma is a common condition in children where there is heterogeneity in response to treatment with inhaled corticosteroids (ICS), long acting beta agonists (LABA) and leukotriene receptor antagonists (LTRA) \(^1\)\(^2\). Some of this heterogeneity may reflect genetic variations within the population, and variants in the gene coding for the beta 2 adrenoceptor (ADRB2) have been associated with increased risk for symptoms \(^3\)\(^-\)\(^5\). Of particular interest is the single nucleotide polymorphism (SNP) rs1042713, a Gly to Arg amino acid substitution at the position 16 of the ADRB2 gene, which has been associated with differences in pulmonary function responsiveness to short acting beta agonists in children \(^6\)\(^-\)\(^9\) and the underlying mechanism of enhanced down-regulation and uncoupling of beta-2 receptors is thought to reflect an altered response to short and long acting beta agonists (SABA and LABA).

Although the SNP rs1042713 appears to alter physiological and clinical response to SABA and LABA in paediatric populations, the clinical relevance of this association remains unclear. In two clinical trials there was no evidence for an association between the A allele of rs1042713 (Arg16 amino acid) and increased symptom score \(^1\)\(^-\)\(^7\). There is inconsistent evidence from observational studies that this SNP may be relevant to exacerbations. In children, the homozygous G/G genotype of rs1042713 has been linked with increased risk for hospitalisation\(^10\), reduced bronchodilator response to short acting beta agonists\(^9\), prolonged stay in hospital \(^11\) and intensive care unit stay \(^12\) after presentation with acute asthma, whilst the heterozygous genotype of rs1042713 has been linked with increased risk for intubation for acute asthma \(^13\). Two other groups have observed associations between A/A genotype of rs1042713 and increased exacerbations among those treated with LABA \(^3\)\(^-\)\(^4\).
but this was not confirmed in a third population\(^{(14)}\). These studies have also observed increased exacerbation risk \(^{(3)}\) and poorer asthma control \(^{(4)}\) among those children homozygous for A/A for the SNP rs1042713 in receipt of ICS (but not LABA). In one study \(^{(3)}\), there was evidence that concomitant LTRA treatment might negate any increased risk for exacerbation associated with LABA treatment, while those children who are homozygous for Arg16 had better asthma outcomes when treated with LTRA rather than LABA in addition to ICS \(^{(15)}\). Prospective studies undertaken in adult populations have found no evidence for LABA treatment being associated with adverse outcomes when added to ICS\(^{(16-18)}\).

To better understand the interactions between the SNP rs1042713 of ADRB2 and asthma treatment, we undertook a meta-analysis of results from five previously described populations \(^{(19)}\). Our hypothesis was that there is an interaction between the A allele of rs1042713 (Arg16 amino acid) and treatment with LABA, but not LTRA, for asthma exacerbation risk and that this risk might be further increased by exposure to daily SABA.
METHODS

Study design. Children with asthma were recruited to five cross-sectional studies (BREATHE, GALA II, PAGES, PACMAN and PASS). The BREATHE and PAGES populations were recruited from primary and secondary care in Scotland, PACMAN was recruited from children attending community pharmacists in Netherlands, GALA II recruited children in USA and Puerto Rico who had four Latino grandparents and PASS recruited children with asthma who had adrenal suppression testing in 25 hospitals across the UK. Further details of the study population’s recruitment are presented in the Online Repository. DNA was extracted from saliva or blood and the genotypes for rs1042713 determined. The primary outcome was asthma exacerbation (with reference to six months in BREATHE, PAGES and PASS and 12 months in GALA II and PACMAN). Asthma treatment was categorised thus: (i) as required (prn) SABA but no preventer treatment (ii) ICS monotherapy plus prn SABA (iii) ICS plus prn SABA and LABA (iv) ICS plus prn SABA and LTRA and (v) ICS plus prn SABA, LABA and LTRA. As previously \(^{(5)}\), as required SABA was categorised as at least once daily or less frequently. Approval was obtained from medical research ethics committees from each institute prior to recruitment. All participants gave verbal assent and parents or participants gave written consent as appropriate.

Definitions of exacerbation. For BREATHE and PAGES the definition of exacerbation was at least one of the following in the previous six months in the context of asthma symptoms: hospital admission, course of oral steroids or absence from school. For GALA, an exacerbation was defined as at least one of the following during the previous 12 months: oral corticosteroid rescue treatment, hospitalisation or need to seek emergency asthma care. For PACMAN, an exacerbation was defined as an asthma-related visit to emergency
department and/or prescribed a course of oral steroids in the past twelve months. The
definition of exacerbation for PASS was at least one course of rescue oral steroids in the
previous six months.

**DNA collection, extraction and analysis.** For BREATHE, PACMAN and PAGES, saliva was
collected in commercially available pots (Oragene, DNA Genotech, Ontario, Canada) DNA
was prepared using the Qiagen Dneasy 96 kit, and genotypes were determined in the
Dundee laboratory using Taqman based allelic discrimination assays on an ABI 7700
sequence detection system, as described previously\(^{(3)}\). For GALA II, DNA was extracted from
whole blood and the Axiom® LAT1 array (World Array 4, Affymetrix, Santa Clara, CA) was
used to determine genome wide-genotype data as described elsewhere\(^{(20)}\). For PASS, the
Illumina Human OmniExpressExome-8 v1.0 chip (Illumina, San Diego, CA) was used for
genotyping.

**Statistical analysis.** The primary outcome was recent exacerbation and this was related to
genotype in logistic models. An additive model \(^{(3)}\) was used, i.e. a gene/dosage effect for the
A allele [Arg16 aminoacid] which adjusted for confounders (i.e. gender, age, second hand
smoke exposure \(^{(3)}\)). Each population was stratified by treatment and risk for exacerbation
per genotype was calculated in each treatment group. Daily SABA use was recorded for
BREATHE, PACMAN and PAGES and here an interaction as sought for SABA treatment x
genotype. Regression analyses in GALA II included the same covariates as in the other
studies, but additionally we included estimates of global African and Native American
genetic ancestry to avoid confusion due to population stratification. Standard statistical
software was used (SPSS version 22.0.0.1). The meta-analysis of data from the five
populations was performed using a fixed-effect (inverse variance–weighted) model, where
the effect size estimates, β coefficients, are weighted by their estimated standard errors using GWAMA software\textsuperscript{(21)}. We estimated the power of the study to detect the associations with exacerbations following the methodology of Purcell \textit{et al} \textsuperscript{(22)}. Our power calculations provide the maximal power we could obtain from the meta-analysis of the cohorts at the significance level of 5%. The odd ratios of 1.2, 1.5 and 3 were selected based on initial results from the BREATHE trial. With the exception of the ICS+LTRA treatment group, all strata were sufficiently powered to detect an odds ratio of 1.5 or above (See table I in the Online Repository). Forest plots were generated with the package \textit{rmeta} for R. A p value of <0.05 was assumed to be significant.
RESULTS

Study subjects

Genotype, treatment and exacerbation data were available in 4226 children including 1210 from BREATHE, 1171 from GALA II, 760 from PACMAN, 695 from PAGES and 390 from PASS, table I. The Gly16Arg polymorphism was in HWE for all cohorts with the exception of BREATHE (exact test p=0.012) considered as a whole, but it was in HWE in the group of children that did not have exacerbations (p=0.624). The minor allele frequency (MAF) for GALA II was higher when compared to the three UK cohorts (0.45 vs 0.37) p=1x10^{-10}, and intermediate for the PACMAN population. Regardless of treatment, across the five populations the additive model found an increased risk for exacerbation for each copy of the A allele amounting to 1.11 [1.01, 1.22] p=0.035, n=4226 (See table II in the Online Repository).

Risk of exacerbation across maintenance treatment groups

The odds ratio for exacerbation was 1.52 [1.17, 1.99] for each copy of the A allele among the 637 children treated with ICS plus LABA, table II. The risk for exacerbation was not increased among other treatment groups, table II. Table III presents the proportion of children with exacerbations stratified by population, treatment and genotype. The analysis for children treated with ICS plus LABA had >90% power to detect an association with increased risk for exacerbation at the significance level of 5% (Table I in the Online Repository). An analysis of local African ancestry at the Gly16Arg locus was undertaken in the GALA II population to examine if the number of chromosomes indicative of African ancestry at this locus was associated with increased exacerbations. There was no
association of local African ancestry with exacerbations in GALA II in the overall population
(OR=1.17, 95% CI: 0.89-1.53, p=0.270) or in the group of patients treated with ICS plus LABA
(OR=1.78, 95% CI: 0.58-5.49, p=0.316).

Risk of exacerbation in relation to SABA use

Among the 822 children in receipt of daily SABA (including 56 who were not on ICS, LABA or
LTRA) there was no evidence of increased risk in the additive model (OR 1.01 [0.79, 1.31],
see table III in the Online Repository). Among those children in receipt of ICS plus LABA
there was no evidence of any additional increased risk in relation to each A allele for
exacerbations among those taking daily SABA (see table IV in the Online Repository).

Asthma control scores and Arg16 homozygous genotype

The risk for poorly controlled asthma (as evidence by the asthma control questionnaire 6
score >1.5) was increased among A/A homozygotes prescribed ICS only within the cohort
PACMAN (OR 2.15) \(^4\). Within the PAGES population 63% (282/446) were poorly controlled
(as evidenced by Children’s Asthma Control Test score <20) and there was no increase in risk
for poor control for A/A homozygotes among any treatment groups.
DISCUSSION

Genetic epidemiology is complicated by inconsistent findings between populations. Therefore replication of findings across different populations is crucial to generalising results \(^{(23)}\). Associations between SNP rs1042713 and LABA and SABA treatment have been previously reported in evaluations of the first 546 children recruited to BREATHE\(^{(3)}\) and the first 597 recruited to PACMAN\(^{(4)}\) (data from 1210 and 760 included in the present report respectively). However, the results of other studies in adults were in apparent conflict with the above observations. This meant that, prior to this study, the important clinical question of whether or not there is a need to progress to further randomised controlled trials assessing benefit with testing for SNP rs1042713 in the clinical setting had not been resolved. This study combined data from five cohorts of children with asthma from white European and Hispanic/Latino populations to explore interactions between exposures to different asthma medications and the SNP rs1042713 for risk of asthma exacerbation. We analysed data from 4226 children and draw three conclusions. First, among children exposed to ICS plus LABA as dual combination therapy there was a 52% increased risk for exacerbation for each copy of the A allele. Second, the interaction between the A allele and exposure to LABA was not present when LTRA treatment was also co-prescribed as triple therapy. Third, there was no evidence that daily SABA usage in addition to ICS plus LABA was associated with any increased further risk for exacerbation among children carrying at least one A allele. The combined incidence of A/G heterozygous and A/A homozygous genotype is approximately 60% and these observations implicate the SNP rs1042713 as an important factor in the well-recognised heterogeneity of treatment response in children with asthma\(^{(1, 2)}\). This study has established the need for further prospective clinical trials where treatment is stratified by genotype to
move these observations into clinical practice in order to evaluate a more personalised approach to treatment of children with poorly controlled asthma despite treatment with inhaled corticosteroids.

We observed heterogeneity between populations for the relationship between SNP rs1042713 and treatment with ICS plus LABA and risk for exacerbation with the risk being highest in GALA II and lowest in PASS. Although this study was not designed to explain the variability between populations, there was no obvious association between the effect size for exacerbation risk associated with A allele and characteristics of the five populations; for example the children in GALA II and PASS were comparable in terms of age, sex distribution and exacerbation rate. More children in PASS were in receipt of ICS plus LABA compared to GALA II but the hypothesis that exacerbation risk attributable to the A allele is lower for populations where LABA treatment is more prevalent is not supported by observations in the PACMAN and PAGES populations where 19% in each received LABA but the exacerbation risk associated with ICS plus LABA was 2.54 and 1.29 respectively. The heterogeneity between populations, and within populations (1, 2), might give potential insight into the pharmacogenetic mechanism(s) but also highlights the need for stratified treatment in childhood asthma.

The minor allele frequency was substantially higher for children in the GALA II population compared to the three UK populations and, as suggested by previous work (18, 24), we explored the possibility that the increased exacerbation rate associated with the Arg16 allele in LABA-treated GALA II subjects reflected the African ancestry associated with this allele. In our adjustment for measures of ancestry for the analyses of the Gly16Arg locus within the GALA II population we did not find significant evidence that African ancestry was
relevant to the positive correlation between minor allele frequency and prevalence of exacerbation, however our analysis was underpowered and the two-fold increase in risk which was detected might have been significant had our sample size been larger. Our study was not designed to explore how ethnic differences might be relevant to the pharmacogenetics or treatment response to LABA and unfortunately there were insufficient numbers of children with African ancestry in the cohorts other than GALA II to further explore this intriguing hypothesis which merits focussed research in future.

The pharmacogenetics of LABA and SABA are notable for the contrasting effects seen for the Gly16Arg locus on acute versus chronic SABA. There has been considerable consistency in the observed effects of Gly16Arg on acute SABA response with many studies showing a similar direction of effect on bronchodilation (favouring Arg16)\(^6, 7, 11, 25, 26\). A seemingly opposite effect (favouring Gly16) was seen for chronic SABA exposure and lung function and asthma control in the Beta Agonists in Mild Asthma (BAGS) \(^27\) and Beta-Adrenergic Response by Genotype (BARGE) \(^28\) studies and another study by Taylor et al \(^29\). The focus of the present study was LABA therapy but we found no evidence for either daily SABA use or the combination of daily SABA plus LABA being linked with increased exacerbation risk for children carrying Arg16 allele. One interpretation of our findings is that the LABA caused effective adrenoceptor blockade and the “adverse” effect of LABA treatment had subsumed any “benefit” of acute SABA treatment for individuals carrying an Arg16 allele.

Although we find evidence here for response to LABA therapy to be modified by the Gly16Arg locus in children, for adults this locus appears to have no effect on response to LABA therapy based on large retrospective analyses and prospective genotype-stratified
clinical trials by Bleecker (16) and the LARGE trial (18). There is evidence that the Gly16 allele might be associated with a bronchoprotective effect in association with LABA treatment (18, 30). The present study was not designed to explore the apparent inconsistency between observations in adults and children but differences in response of children and adults to LABA are well-recognised. The addition of LABA to ICS treatment in adults with poorly controlled asthma is accepted to be superior to alternative treatments (31, 32) but in children the evidence is that LABA are no more effective that addition of LTRA or increase in ICS (1, 33).

Our analysis included a relatively large number of well-characterised children with asthma from five populations and therefore any significant association is likely to be generalizable to other similar populations, perhaps aside from those where there is a higher proportion of individuals of African descent where the A allele is more prevalent. In the literature there are apparently conflicting associations reported between variants of the SNP rs1042713 and response to treatment (3-6, 9, 11) and one explanation for this heterogeneity is that the earlier findings are based on relatively small single populations, i.e. which number less than 1000, and meta-analysis addresses the potential for false positive findings and/or associations which are idiosyncratic for one population. This meta-analysis confirms previously reported increases in the risk for exacerbations among Arg16 homozygotes in receipt of LABA treatment (3, 4). The present study failed to replicate previously reported associations between homozygous genotype A/A and treatment with ICS alone and increased risk for exacerbation (3) or poor asthma control (4), suggesting the possibility of false positive findings. The magnitude of risk for exacerbation associated with ICS and LABA treatment and A allele reported in first 546 children recruited to the BREATHE cohort (3) is slightly
reduced in the larger population (2.1 versus 1.5) but remains significant across all five populations. The five populations included were heterogeneous for asthma outcomes and the results could be generalised to Western European and Hispanic/Latino populations but, given the potential for different associations between rs1042713 and asthma treatment response between different ethnic groups \(^{[26]}\), our results may not be relevant to all populations.

In our analysis we explored the possible additive effect of treatment with daily SABA and LABA for exacerbations, and we have previously reported that either treatment is associated with increased exacerbations for the BREATHE population among Arg/Arg homozygotes\(^{[5]}\). When data were pooled there was no apparent additive effect of SABA on LABA for exacerbation risk for children with one or two Arg alleles. These results should be treated with caution since, even with a relatively large population such as we present here, there were relatively few children with ICS plus LABA and daily SABA exposure and the analysis was probably underpowered and there may be a modest additive effect which we were not able to detect.

The mechanism(s) underlying the association between the Arg16 allele and increased exacerbation in the context of LABA treatment are thought to be mediated by enhanced agonist induced down-regulation and receptor uncoupling, resulting in subsensitivity of response \(^{[34, 35]}\). Our novel finding of no increased risk for exacerbation among A/A homozygotes in receipt of ICS and LABA and LTRA suggests that factors other than ADRB2 down regulation are active since LABA exposure in this group of children might be expected to down regulate ADRB2. It is likely that LTRA merely confer an additional anti-inflammatory effect in individuals exposed to LABA, such that in genetically susceptible...
patients it might be seen as a salutary effect by counteracting the response to LABA. Where the LABA effect is negated (i.e. in Arg/Arg) the additive effect of LTRA will be more evident compared to the setting where LABA effect is more pronounced (i.e. Gly/Gly) and the additive effect of LTRA will be less evident. Indeed in one study using AMP challenge as the primary outcome, there was better protection with ICS/LABA/LTRA as triple therapy compared to dual therapy with ICS/LABA, which was also mirrored by effects on exhaled NO and blood eosinophils, suggesting that the apparent counteracting role of LTRA may arise from the additional anti-inflammatory effects of LTRA \(^{(26)}\).

This study has a number of limitations, which should be considered when these results are interpreted. First, the associations described here do not imply causation but the findings are consistent with the results of a small genotype stratified randomised controlled trial, which found favourable outcomes among A/A homozygotes taking LTRA compared to LABA over a period of 12 months when used as add on therapy to ICS \(^{(15)}\). Second, although we are able to be conclusive as to the nature of the relationship between exposure to LABA and A/A homozygous genotype and exacerbation, we cannot exclude the possibility that there may be a small additive relationship between SABA and LABA for exacerbation. The relationship between LABA, SABA and exacerbations will always be a challenge to study since frequent SABA treatment is an indication for LABA therapy but our findings suggest that the magnitude of association with LABA is greater than SABA, which perhaps is not surprising given the potential impact more prolonged receptor occupancy conferred by LABA than SABA, especially in genetically susceptible individuals. Third, more detailed genotyping of the ADRB2 locus a genome wide association study (GWAS) or haplotype analysis might have yielded additional insight into the relationship between genetic
variations of the ADRB2 but neither GWAS or haplotype data were available for all cohorts and we focussed on the SNP rs1042713 since there is a large literature which indicates that this is associated with outcomes for asthma treatment. A fourth limitation is that we have assumed that treatment has been assigned based on the same criteria and it is possible that in some cohorts, children with more severe asthma and at increased risk for exacerbations might not have received LABA treatment but this would tend to underestimate the effect of the interaction between LABA treatment and the SNP rs1042713 for exacerbations. A fifth limitation is that rare variants were not genotyped which could also have an impact on adverse events during LABA therapy; however, these cohorts were not powered for a rare variant analysis and the rare variants identified by Ortega et al. (38) occurred in the background of Gly16, not Arg16. Finally, the polymorphism Gly16Arg allele frequency was not in Hardy Weinberg Equilibrium for the whole BREATHE cohort but the consistency of the results across the cohorts suggests that the deviation within this single cohort did not substantially influence the overall results. Furthermore, Gly16Arg is an inconsistently replicated and, at best, weak locus for asthma severity so it does not seem plausible that selection for exacerbation (the primary outcome and linked to asthma severity) in this study is the cause for the deviation from HWE seen in the BREATHE cohort. Since Gly16Arg is a better established pharmacogenetic locus, a more plausible outcome which would influence deviations from HWE is exacerbations or symptoms despite frequent SABA use or LABA use, but this represents a small percentage of the BREATHE cohort (18% and 11%, respectively).

In conclusion, children with asthma on ICS plus LABA were at 52% increased risk for exacerbation in the previous 6-12 months for each A allele (Arg16 amino acid) compared to G/G homozygotes (Gly16/Gly16). Knowing that there are 1 million children in the UK with
asthma and 10% of these are prescribed LABA (3948) and 60% of these carry at least one Arg16 allele, there are approximately 60,000 children in the UK today, and approximately 25,000 in the Netherlands, who might be at risk from the morbidity of exacerbation which is preventable by treatment with either no LABA or perhaps with the addition of LTRA if genotyping of rs1042713 could be made available at the point of prescribing. Put another way, and assuming that at least one third of the UK national healthcare costs attributable to childhood asthma are due to urgent care (40, 41 39, 40), stratified treatment might reduce the annual direct costs to the UK National Health Service for the management of childhood asthma exacerbations by 10% (i.e. a 50% reduction in 60% of the population). Whilst there are no recent published costs for the management of childhood asthma, costs in the US have been estimated at $791 per child per annum in 2005 (41 40) and to total £150 million in the UK in 1997 (42 41). It is thus likely that stratified treatment in childhood asthma will save tens of millions of pounds in direct healthcare costs. Not all asthmatics who inherit an A allele will experience increased morbidity with LABA treatment and this might be explained by rare variants, perhaps at the same locus (3842), pathway related variation (43), epigenetic mechanisms or treatment adherence.
REFERENCES


22. Purcell S, Cherny SS, Sham PC. Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003;19:149-50.


Table I. Comparison of details of children in each of the five study populations. *Dutch, Moroccan and Turkish ethnicities were considered Caucasian in PACMAN. †ethnicity data were not available for all participants in PAGES. ‡daily short acting beta agonist status was not determined in GALA II and PASS.¶ minor allele frequency = frequency of minor allele homozygous genotype + (frequency of heterozygous genotype)/2

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>BREATHE n=1210</th>
<th>GALA II n=1171</th>
<th>PACMAN n=760</th>
<th>PAGES n=695</th>
<th>PASS n=390</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Male (n)</td>
<td>60% (725)</td>
<td>58% (676)</td>
<td>63% (478)</td>
<td>57% (399)</td>
<td>56% (172)</td>
</tr>
<tr>
<td>% Exposed to tobacco smoke at home (n)</td>
<td>35% (424)</td>
<td>21% (242)</td>
<td>14% (108)</td>
<td>21% (146)</td>
<td>36% (108)</td>
</tr>
<tr>
<td>Mean age, (SD) years</td>
<td>9.7 (3.8)</td>
<td>11.9 (2.7)</td>
<td>8.7 (2.3)</td>
<td>9.8 (3.7)</td>
<td>11.1 (4.0)</td>
</tr>
<tr>
<td>Recent exacerbation</td>
<td>44% (536)</td>
<td>65% (763)</td>
<td>10% (76)</td>
<td>47% (323)</td>
<td>75% (295)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>% Caucasian</th>
<th>% Hispanic</th>
<th>% African</th>
<th>% Other (including mixed)</th>
<th>Minor allele frequency¶</th>
<th>A/A (Arg/Arg) (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0%</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
<td>0.37</td>
<td>15% (175)</td>
</tr>
<tr>
<td></td>
<td>90%*</td>
<td>0.4%</td>
<td>1%</td>
<td>8.6%</td>
<td>0.45</td>
<td>20% (234)</td>
</tr>
<tr>
<td></td>
<td>93%†</td>
<td>0%</td>
<td>0%</td>
<td>7%</td>
<td>0.41</td>
<td>15% (115)</td>
</tr>
<tr>
<td></td>
<td>99%</td>
<td>0%</td>
<td>0%</td>
<td>1%</td>
<td>0.37</td>
<td>14% (96)</td>
</tr>
<tr>
<td></td>
<td>(681/753)</td>
<td>(3/753)</td>
<td>(8/753)</td>
<td>(61/753)</td>
<td>(26/384)</td>
<td>(2/390)</td>
</tr>
</tbody>
</table>

* * *
<table>
<thead>
<tr>
<th>rs1042713 genotype</th>
<th>A/G (Arg/Gly) (n)</th>
<th>43% (515)</th>
<th>49% (579)</th>
<th>51% (388)</th>
<th>46% (321)</th>
<th>43% (169)</th>
</tr>
</thead>
<tbody>
<tr>
<td>G/G (Gly/Gly) (n)</td>
<td>43% (520)</td>
<td>31% (358)</td>
<td>34% (257)</td>
<td>40% (278)</td>
<td>41% (160)</td>
<td></td>
</tr>
<tr>
<td>% Short acting beta agonist alone (n)</td>
<td>18% (218)</td>
<td>42% (490)</td>
<td>10% (73)</td>
<td>7% (51)</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>% Inhaled corticosteroid, ICS, (n)</td>
<td>58% (698)</td>
<td>24% (283)</td>
<td>63% (476)</td>
<td>40% (273)</td>
<td>7% (28)</td>
<td></td>
</tr>
<tr>
<td>% ICS plus long acting beta agonist, LABA, (n)</td>
<td>11% (138)</td>
<td>10% (122)</td>
<td>19% (147)</td>
<td>19% (134)</td>
<td>33% (96)</td>
<td></td>
</tr>
<tr>
<td>% ICS plus leukotriene receptor antagonist, LTRA, (n)</td>
<td>5% (65)</td>
<td>15% (177)</td>
<td>3% (23)</td>
<td>9% (65)</td>
<td>8% (24)</td>
<td></td>
</tr>
<tr>
<td>% ICS plus LABA plus LTRA, (n)</td>
<td>8% (91)</td>
<td>9% (99)</td>
<td>5% (41)</td>
<td>24% (169)</td>
<td>59% (230)</td>
<td></td>
</tr>
<tr>
<td>% with daily short acting beta agonist dosing, (n)</td>
<td>21% (250)</td>
<td>†</td>
<td>49% (364)</td>
<td>30% (209)</td>
<td>†</td>
<td></td>
</tr>
</tbody>
</table>
Table II. Odds ratio for exacerbation per copy of the A allele (Arg16 amino acid). Results are from logistic regression models which adjusted for sex, age and exposure to second hand smoke at home. SABA=short acting beta agonist. ICS =inhaled corticosteroids. LABA= long acting beta agonist. LTRA=leukotriene receptor antagonist. *There were no children in PASS on SABA alone.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Odds ratio [95% confidence interval] for exacerbation per A allele (referenced to none)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BREATHE</td>
</tr>
<tr>
<td>SABA alone</td>
<td>0.87 [0.54, 1.40] (n=218)</td>
</tr>
<tr>
<td>ICS alone</td>
<td>1.15 [0.92, 1.43] (n=698)</td>
</tr>
<tr>
<td>ICS+LABA</td>
<td>1.52 [0.92, 2.50] (n=138)</td>
</tr>
<tr>
<td>ICS+LTRA</td>
<td>1.86 [0.85, 4.08] (n=65)</td>
</tr>
<tr>
<td>ICS+LABA+LTRA</td>
<td>1.03 [0.54, 1.96] (n=91)</td>
</tr>
</tbody>
</table>
Table III. The proportion (percentage) of children with exacerbations stratified by treatment class and SNP rs1042713.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>BREATHE</th>
<th>GALA II</th>
<th>PACMAN</th>
<th>PAGES</th>
<th>PASS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA</td>
<td>AG</td>
<td>GG</td>
<td>AA</td>
<td>AG</td>
</tr>
<tr>
<td>SABA alone</td>
<td>7/29 (24%)</td>
<td>28/101 (28%)</td>
<td>25/88 (28%)</td>
<td>57/92 (62%)</td>
<td>150/241 (62%)</td>
</tr>
<tr>
<td>ICS alone</td>
<td>52/98 (53%)</td>
<td>121/296 (41%)</td>
<td>126/304 (41%)</td>
<td>43/62 (69%)</td>
<td>93/151 (62%)</td>
</tr>
<tr>
<td>ICS+LABA</td>
<td>18/22 (82%)</td>
<td>25/55 (46%)</td>
<td>33/61 (54%)</td>
<td>25/30 (83%)</td>
<td>43/56 (77%)</td>
</tr>
<tr>
<td>ICS+LTRA</td>
<td>8/11 (73%)</td>
<td>18/26 (69%)</td>
<td>15/28 (54%)</td>
<td>22/34 (65%)</td>
<td>59/81 (73%)</td>
</tr>
<tr>
<td>ICS+LABA+LTRA</td>
<td>11/15 (73%)</td>
<td>23/37 (62%)</td>
<td>26/39 (67%)</td>
<td>13/16 (81%)</td>
<td>37/50 (74%)</td>
</tr>
</tbody>
</table>
Childhood asthma exacerbations and the Arg-16 beta2 receptor polymorphism: a meta-analysis stratified by treatment

Steve Turner MD1, Ben Francis PhD2, Susanne Vijverberg PhD3, Maria Pino-Yanes PhD4,5, Anke H Maitland-van der Zee PhD5, Kaninika Basu MD6, Lauren Bignell MBBS6, Somnath Mukhopadhyay MB6,7, Roger Tavendale PhD7, Colin Palmer PhD7, Daniel Hawcutt PhD8, Munir Pirmohamed PhD9, Esteban G Burchard MD MPH10,11 and Brian Lipworth MD12 on behalf of the Pharmacogenomics in Childhood Asthma consortium

1Child Health, University of Aberdeen
2Department of Biostatistics, University of Liverpool, Liverpool
3Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht
4CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
5Research Unit, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, Spain
6Academic Department of Paediatrics, Royal Alexandra Children’s Hospital, Brighton and Sussex Medical School, Brighton, United Kingdom.
7Population Pharmacogenetics Group, University of Dundee
8Department of Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool, Liverpool
9Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool
10Department of Bioengineering and Therapeutic Sciences and Medicine, University of California, San Francisco, USA
11Center for Genes, Environment and Health, University of California, San Francisco, USA
12Asthma and allergy Research Group, University of Dundee
Contact details: Dr S Turner, Child Health, Royal Aberdeen Children’s Hospital, Aberdeen,
AB25 2ZG tel +44 1224 438475, fax +44 1224 438469, s.w.turner@abdn.ac.uk

Funding sources. There were no funds for the present analysis and the individual cohorts
were funded as follows:

BREATHE was funded by Scottish Enterprise Tayside, the Gannochy Trust, the Perth and
Kinross City Council and Brighton and Sussex Medical School.

GALA II. The contribution from GALA II to this work was supported by grants from National
Institutes of Health to E.G.B.: the National Heart, Lung and Blood Institute (HL088133,
HL078885, HL004464, HL104608 and HL117004); the National Institute of Environmental
Health Sciences (ES015794); the National Institute on Minority Health and Health Disparities
(MD006902); the National Institute of General Medical Sciences (GM007546). E.G.B was also
funded by the American Asthma Foundation, the RWJF Amos Medical Faculty Development
Award, the Sandler Foundation and the Flight Attendant Medical Research Institute. MPY
was supported by a postdoctoral fellowship from Fundacion Ramon Areces
(www.fundacionareces.es).

PACMAN was funded by a strategic alliance between GSK and Utrecht Institute for
Pharmaceutical Sciences.

PAGES was funded by the Chief Scientist Officer for Scotland.

PASS was funded by the UK department of health through the "NHS Chair of
Pharmacogenomics

None of the authors has any financial relationship with a biotechnology and/or
pharmaceutical manufacturer that has an interest in the subject matter or materials
discussed in the submitted manuscript.

Running head: ADRB2 and childhood asthma exacerbations

Word count for main body of manuscript: 2793
ABSTRACT

Background. The Gly-to-Arg substitution at the 16 position (rs1042713) in the beta 2 adrenoceptor (ADRB2) gene is associated with enhanced down-regulation and uncoupling of beta-2 receptors.

Objectives. To undertake a meta-analysis to test the hypothesis that there is an interaction between the A allele of rs1042713 (Arg16 amino acid) and long acting beta agonist (LABA) exposure for asthma exacerbations in children.

Methods. Children with diagnosed asthma were recruited in five populations (BREATHE, GALA II, PACMAN, PAGES and PASS). A history of recent exacerbation and asthma treatment were determined from questionnaire data. DNA was extracted and the Gly16Arg genotype determined.

Results. Data from 4226 children of white Northern European and Latino origin were analysed and the odds ratio for exacerbation increased by 1.52 [1.17, 1.99] p=0.0021 for each copy of the A allele among the 637 children treated with inhaled corticosteroids (ICS) plus LABA but not for treatment with ICS alone (n=1758), nor ICS plus leukotriene receptor antagonist (LTRA, n=354) or ICS plus LABA plus LTRA (n=569).

Conclusions. The use of LABA as “add-on controller”, but not LTRA, is associated with increased risk of asthma exacerbations in children carrying one or two A alleles at rs1042713. Prospective genotype stratified clinical trials are now required to explore the potential role of rs1042713 genotyping for personalised asthma therapy in children.

Key words: Adrenergic receptors; Asthma; Child; Disease exacerbation; Therapeutics.
Clinical trials are required to determine whether treatment stratified by rs1042713 will reduce asthma exacerbation risk in children with one or two A alleles.
This meta-analysis finds increased asthma exacerbation risk for children who carry ≥ 1 A allele of rs1042713, but only in the context of treatment with inhaled corticosteroids and long acting beta agonist.
ABBREVIATIONS

ADRB2 Beta 2 Adrenoceptor

LABA Long Acting Beta Agonists

LTRA Leukotriene Receptor Antagonist

ICS Inhaled Corticosteroids

MAF Minor Allele Frequency

PAGES Paediatric Asthma Gene Environment Study

PASS Pharmaco genetics of Adrenal Suppression with inhaled Steroid study

SABA Short Acting Beta Agonists

SNP Single Nucleotide Polymorphism
INTRODUCTION

Asthma is a common condition in children where there is heterogeneity in response to treatment with inhaled corticosteroids (ICS), long acting beta agonists (LABA) and leukotriene receptor antagonists (LTRA) \(^1\). Some of this heterogeneity may reflect genetic variations within the population, and variants in the gene coding for the beta 2 adrenoceptor (\(ADRB2\)) have been associated with increased risk for symptoms \(^3\)-\(^5\). Of particular interest is the single nucleotide polymorphism (SNP) rs1042713, a Gly to Arg amino acid substitution at the position 16 of the \(ADRB2\) gene, which has been associated with differences in pulmonary function responsiveness to short acting beta agonists in children \(^6\)-\(^9\) and the underlying mechanism of enhanced down-regulation and uncoupling of beta-2 receptors is thought to reflect an altered response to short and long acting beta agonists (SABA and LABA).

Although the SNP rs1042713 appears to alter physiological and clinical response to SABA and LABA in paediatric populations, the clinical relevance of this association remains unclear. In two clinical trials there was no evidence for an association between the A allele of rs1042713 (Arg16 amino acid) and increased symptom score \(^1\),\(^7\). There is inconsistent evidence from observational studies that this SNP may be relevant to exacerbations. In children, the homozygous G/G genotype of rs1042713 has been linked with increased risk for hospitalisation \(^10\), reduced bronchodilator response to short acting beta agonists \(^9\), prolonged stay in hospital \(^11\) and intensive care unit stay \(^12\) after presentation with acute asthma, whilst the heterozygous genotype of rs1042713 has been linked with increased risk for intubation for acute asthma \(^13\). Two other groups have observed associations between A/A genotype of rs1042713 and increased exacerbations among those treated with LABA \(^3\),\(^4\).
but this was not confirmed in a third population\textsuperscript{(14)}. These studies have also observed increased exacerbation risk\textsuperscript{(3)} and poorer asthma control\textsuperscript{(4)} among those children homozygous for A/A for the SNP rs1042713 in receipt of ICS (but not LABA). In one study\textsuperscript{(3)}, there was evidence that concomitant LTRA treatment might negate any increased risk for exacerbation associated with LABA treatment, while those children who are homozygous for Arg16 had better asthma outcomes when treated with LTRA rather than LABA in addition to ICS\textsuperscript{(15)}. Prospective studies undertaken in adult populations have found no evidence for LABA treatment being associated with adverse outcomes when added to ICS\textsuperscript{(16-18)}.

To better understand the interactions between the SNP rs1042713 of ADRB2 and asthma treatment, we undertook a meta-analysis of results from five previously described populations\textsuperscript{(19)}. Our hypothesis was that there is an interaction between the A allele of rs1042713 (Arg16 amino acid) and treatment with LABA, but not LTRA, for asthma exacerbation risk and that this risk might be further increased by exposure to daily SABA.
METHODS

Study design. Children with asthma were recruited to five cross-sectional studies (BREATHE, GALA II, PAGES, PACMAN and PASS). The BREATHE and PAGES populations were recruited from primary and secondary care in Scotland, PACMAN was recruited from children attending community pharmacists in Netherlands, GALA II recruited children in USA and Puerto Rico who had four Latino grandparents and PASS recruited children with asthma who had adrenal suppression testing in 25 hospitals across the UK. Further details of the study population’s recruitment are presented in the Online Repository. DNA was extracted from saliva or blood and the genotypes for rs1042713 determined. The primary outcome was asthma exacerbation (with reference to six months in BREATHE, PAGES and PASS and 12 months in GALA II and PACMAN). Asthma treatment was categorised thus: (i) as required (prn) SABA but no preventer treatment (ii) ICS monotherapy plus prn SABA (iii) ICS plus prn SABA and LABA (iv) ICS plus prn SABA and LTRA and (v) ICS plus prn SABA, LABA and LTRA. As previously (5), as required SABA was categorised as at least once daily or less frequently. Approval was obtained from medical research ethics committees from each institute prior to recruitment. All participants gave verbal assent and parents or participants gave written consent as appropriate.

Definitions of exacerbation. For BREATHE and PAGES the definition of exacerbation was at least one of the following in the previous six months in the context of asthma symptoms: hospital admission, course of oral steroids or absence from school. For GALA, an exacerbation was defined as at least one of the following during the previous 12 months: oral corticosteroid rescue treatment, hospitalisation or need to seek emergency asthma care. For PACMAN, an exacerbation was defined as an asthma-related visit to emergency
department and/or prescribed a course of oral steroids in the past twelve months. The
definition of exacerbation for PASS was at least one course of rescue oral steroids in the
previous six months.

**DNA collection, extraction and analysis.** For BREATHE, PACMAN and PAGES, saliva was
collected in commercially available pots (Oragene, DNA Genotech, Ontario, Canada) DNA
was prepared using the Qiagen Dneasy 96 kit, and genotypes were determined in the
Dundee laboratory using Taqman based allelic discrimination assays on an ABI 7700
sequence detection system, as described previously\(^{[3]}\). For GALA II, DNA was extracted from
whole blood and the Axiom® LAT1 array (World Array 4, Affymetrix, Santa Clara, CA) was
used to determine genome wide-genotype data as described elsewhere\(^{[20]}\). For PASS, the
Illumina Human OmniExpressExome-8 v1.0 chip (Illumina, San Diego, CA) was used for
genotyping.

**Statistical analysis.** The primary outcome was recent exacerbation and this was related to
genotype in logistic models. An additive model \(^{[3]}\) was used, i.e. a gene/dosage effect for the
A allele [Arg16 aminoacid] which adjusted for confounders (i.e. gender, age, second hand
smoke exposure \(^{[3]}\)). Each population was stratified by treatment and risk for exacerbation
per genotype was calculated in each treatment group. Daily SABA use was recorded for
BREATHE, PACMAN and PAGES and here an interaction as sought for SABA treatment x
genotype. Regression analyses in GALA II included the same covariates as in the other
studies, but additionally we included estimates of global African and Native American
genetic ancestry to avoid confusion due to population stratification. Standard statistical
software was used (SPSS version 22.0.0.1). The meta-analysis of data from the five
populations was performed using a fixed-effect (inverse variance–weighted) model, where
the effect size estimates, $\beta$ coefficients, are weighted by their estimated standard errors using GWAMA software\textsuperscript{(21)}. We estimated the power of the study to detect the associations with exacerbations following the methodology of Purcell et al \textsuperscript{(22)}. Our power calculations provide the maximal power we could obtain from the meta-analysis of the cohorts at the significance level of 5%. The odd ratios of 1.2, 1.5 and 3 were selected based on initial results from the BREATHE trial. With the exception of the ICS+LTRA treatment group, all strata were sufficiently powered to detect an odds ratio of 1.5 or above (See table I in the Online Repository). Forest plots were generated with the package \textit{rmeta} for R. A p value of <0.05 was assumed to be significant.
RESULTS

Study subjects

Genotype, treatment and exacerbation data were available in 4226 children including 1210 from BREATHE, 1171 from GALA II, 760 from PACMAN, 695 from PAGES and 390 from PASS, table I. The Gly16Arg polymorphism was in HWE for all cohorts with the exception of BREATHE (exact test p=0.012) considered as a whole, but it was in HWE in the group of children that did not have exacerbations (p=0.624). The minor allele frequency (MAF) for GALA II was higher when compared to the three UK cohorts (0.45 vs 0.37) p=1x10^{-10}, and intermediate for the PACMAN population. Regardless of treatment, across the five populations the additive model found an increased risk for exacerbation for each copy of the A allele amounting to 1.11 [1.01, 1.22] p=0.035, n=4226 (See table II in the Online Repository).

Risk of exacerbation across maintenance treatment groups

The odds ratio for exacerbation was 1.52 [1.17, 1.99] for each copy of the A allele among the 637 children treated with ICS plus LABA, table II. The risk for exacerbation was not increased among other treatment groups, table II. Table III presents the proportion of children with exacerbations stratified by population, treatment and genotype. The analysis for children treated with ICS plus LABA had >90% power to detect an association with increased risk for exacerbation at the significance level of 5% (Table I in the Online Repository). An analysis of local African ancestry at the Gly16Arg locus was undertaken in the GALA II population to examine if the number of chromosomes indicative of African ancestry at this locus was associated with increased exacerbations. There was no
association of local African ancestry with exacerbations in GALA II in the overall population (OR=1.17, 95% CI: 0.89-1.53, p=0.270) or in the group of patients treated with ICS plus LABA (OR=1.78, 95% CI: 0.58-5.49, p=0.316).

Risk of exacerbation in relation to SABA use

Among the 822 children in receipt of daily SABA (including 56 who were not on ICS, LABA or LTRA) there was no evidence of increased risk in the additive model (OR 1.01 [0.79, 1.31], see table III in the Online Repository). Among those children in receipt of ICS plus LABA there was no evidence of any additional increased risk in relation to each A allele for exacerbations among those taking daily SABA (see table IV in the Online Repository).

Asthma control scores and Arg16 homozygous genotype

The risk for poorly controlled asthma (as evidence by the asthma control questionnaire 6 score >1.5) was increased among A/A homozygotes prescribed ICS only within the cohort PACMAN (OR 2.15). Within the PAGES population 63% (282/446) were poorly controlled (as evidenced by Children’s Asthma Control Test score <20) and there was no increase in risk for poor control for A/A homozygotes among any treatment groups.
DISCUSSION

Genetic epidemiology is complicated by inconsistent findings between populations. Therefore replication of findings across different populations is crucial to generalising results \(^{(23)}\). Associations between SNP rs1042713 and LABA and SABA treatment have been previously reported in evaluations of the first 546 children recruited to BREATHE\(^{(3)}\) and the first 597 recruited to PACMAN\(^{(4)}\) (data from 1210 and 760 included in the present report respectively). However, the results of other studies in adults were in apparent conflict with the above observations. This meant that, prior to this study, the important clinical question of whether or not there is a need to progress to further randomised controlled trials assessing benefit with testing for SNP rs1042713 in the clinical setting had not been resolved. This study combined data from five cohorts of children with asthma from white European and Hispanic/Latino populations to explore interactions between exposures to different asthma medications and the SNP rs1042713 for risk of asthma exacerbation. We analysed data from 4226 children and draw three conclusions. First, among children exposed to ICS plus LABA as dual combination therapy there was a 52% increased risk for exacerbation for each copy of the A allele. Second, the interaction between the A allele and exposure to LABA was not present when LTRA treatment was also co-prescribed as triple therapy. Third, there was no evidence that daily SABA usage in addition to ICS plus LABA was associated with any increased further risk for exacerbation among children carrying at least one A allele. The combined incidence of A/G heterozygous and A/A homozygous genotype is approximately 60% and these observations implicate the SNP rs1042713 as an important factor in the well-recognised heterogeneity of treatment response in children with asthma\(^{(1,2)}\). This study has established the need for further prospective clinical trials where treatment is stratified by genotype to
move these observations into clinical practice in order to evaluate a more personalised approach to treatment of children with poorly controlled asthma despite treatment with inhaled corticosteroids.

We observed heterogeneity between populations for the relationship between SNP rs1042713 and treatment with ICS plus LABA and risk for exacerbation with the risk being highest in GALA II and lowest in PASS. Although this study was not designed to explain the variability between populations, there was no obvious association between the effect size for exacerbation risk associated with A allele and characteristics of the five populations; for example the children in GALA II and PASS were comparable in terms of age, sex distribution and exacerbation rate. More children in PASS were in receipt of ICS plus LABA compared to GALA II but the hypothesis that exacerbation risk attributable to the A allele is lower for populations where LABA treatment is more prevalent is not supported by observations in the PACMAN and PAGES populations where 19% in each received LABA but the exacerbation risk associated with ICS plus LABA was 2.54 and 1.29 respectively. The heterogeneity between populations, and within populations \(^1,^2\), might give potential insight into the pharmacogenetic mechanism(s) but also highlights the need for stratified treatment in childhood asthma.

The minor allele frequency was substantially higher for children in the GALA II population compared to the three UK populations and, as suggested by previous work \(^18,^24\), we explored the possibility that the increased exacerbation rate associated with the Arg16 allele in LABA-treated GALA II subjects reflected the African ancestry associated with this allele. In our adjustment for measures of ancestry for the analyses of the Gly16Arg locus within the GALA II population we did not find significant evidence that African ancestry was
relevant to the positive correlation between minor allele frequency and prevalence of exacerbation, however our analysis was underpowered and the two-fold increase in risk which was detected might have been significant had our sample size been larger. Our study was not designed to explore how ethnic differences might be relevant to the pharmacogenetics or treatment response to LABA and unfortunately there were insufficient numbers of children with African ancestry in the cohorts other than GALA II to further explore this intriguing hypothesis which merits focussed research in future.

The pharmacogenetics of LABA and SABA are notable for the contrasting effects seen for the Gly16Arg locus on acute versus chronic SABA. There has been considerable consistency in the observed effects of Gly16Arg on acute SABA response with many studies showing a similar direction of effect on bronchodilation (favouring Arg16)\(^6, 7, 11, 25, 26\). A seemingly opposite effect (favouring Gly16) was seen for chronic SABA exposure and lung function and asthma control in the Beta Agonists in Mild Asthma (BAGS)\(^{27}\) and Beta-Adrenergic Response by Genotype (BARGE)\(^{28}\) studies and another study by Taylor et al\(^{29}\). The focus of the present study was LABA therapy but we found no evidence for either daily SABA use or the combination of daily SABA plus LABA being linked with increased exacerbation risk for children carrying Arg16 allele. One interpretation of our findings is that the LABA caused effective adrenoceptor blockade and the “adverse” effect of LABA treatment had subsumed any “benefit” of acute SABA treatment for individuals carrying an Arg16 allele.

Although we find evidence here for response to LABA therapy to be modified by the Gly16Arg locus in children, for adults this locus appears to have no effect on response to LABA therapy based on large retrospective analyses and prospective genotype-stratified
clinical trials by Bleecker and the LARGE trial. There is evidence that the Gly16 allele might be associated with a bronchoprotective effect in association with LABA treatment. The present study was not designed to explore the apparent inconsistency between observations in adults and children but differences in response of children and adults to LABA are well-recognised. The addition of LABA to ICS treatment in adults with poorly controlled asthma is accepted to be superior to alternative treatments but in children the evidence is that LABA are no more effective that addition of LTRA or increase in ICS.

Our analysis included a relatively large number of well-characterised children with asthma from five populations and therefore any significant association is likely to be generalizable to other similar populations, perhaps aside from those where there is a higher proportion of individuals of African descent where the A allele is more prevalent. In the literature there are apparently conflicting associations reported between variants of the SNP rs1042713 and response to treatment and one explanation for this heterogeneity is that the earlier findings are based on relatively small single populations, i.e. which number less than 1000, and meta-analysis addresses the potential for false positive findings and/or associations which are idiosyncratic for one population. This meta-analysis confirms previously reported increases in the risk for exacerbations among Arg16 homozygotes in receipt of LABA treatment. The present study failed to replicate previously reported associations between homozygous genotype A/A and treatment with ICS alone and increased risk for exacerbation or poor asthma control, suggesting the possibility of false positive findings. The magnitude of risk for exacerbation associated with ICS and LABA treatment and A allele reported in first 546 children recruited to the BREATHE cohort is slightly
reduced in the larger population (2.1 versus 1.5) but remains significant across all five populations. The five populations included were heterogeneous for asthma outcomes and the results could be generalised to Western European and Hispanic/Latino populations but, given the potential for different associations between rs1042713 and asthma treatment response between different ethnic groups \[26\], our results may not be relevant to all populations.

In our analysis we explored the possible additive effect of treatment with daily SABA and LABA for exacerbations, and we have previously reported that either treatment is associated with increased exacerbations for the BREATHE population among Arg/Arg homozygotes\[5\]. When data were pooled there was no apparent additive effect of SABA on LABA for exacerbation risk for children with one or two Arg alleles. These results should be treated with caution since, even with a relatively large population such as we present here, there were relatively few children with ICS plus LABA and daily SABA exposure and the analysis was probably underpowered and there may be a modest additive effect which we were not able to detect.

The mechanism(s) underlying the association between the Arg16 allele and increased exacerbation in the context of LABA treatment are thought to be mediated by enhanced agonist induced down-regulation and receptor uncoupling, resulting in subsensitivity of response \[34, 35\]. Our novel finding of no increased risk for exacerbation among A/A homozygotes in receipt of ICS and LABA and LTRA suggests that factors other than \textit{ADRB2} down regulation are active since LABA exposure in this group of children might be expected to down regulate \textit{ADRB2}. It is likely that LTRA merely confer an additional anti-inflammatory effect in individuals exposed to LABA, such that in genetically susceptible
patients it might be seen as a salutary effect by counteracting the response to LABA. Where the LABA effect is negated (i.e. in Arg/Arg) the additive effect of LTRA will be more evident compared to the setting where LABA effect is more pronounced (i.e. Gly/Gly) and the additive effect of LTRA will be less evident. Indeed in one study using AMP challenge as the primary outcome, there was better protection with ICS/LABA/LTRA as triple therapy compared to dual therapy with ICS/LABA, which was also mirrored by effects on exhaled NO and blood eosinophils, suggesting that the apparent counteracting role of LTRA may arise from the additional anti-inflammatory effects of LTRA (36).

This study has a number of limitations, which should be considered when these results are interpreted. First, the associations described here do not imply causation but the findings are consistent with the results of a small genotype stratified randomised controlled trial, which found favourable outcomes among A/A homozygotes taking LTRA compared to LABA over a period of 12 months when used as add on therapy to ICS (15). Second, although we are able to be conclusive as to the nature of the relationship between exposure to LABA and A/A homozygous genotype and exacerbation, we cannot exclude the possibility that there may be a small additive relationship between SABA and LABA for exacerbation. The relationship between LABA, SABA and exacerbations will always be a challenge to study since frequent SABA treatment is an indication for LABA therapy but our findings suggest that the magnitude of association with LABA is greater than SABA, which perhaps is not surprising given the potential impact more prolonged receptor occupancy conferred by LABA than SABA, especially in genetically susceptible individuals. Third, more detailed genotyping of the ADRB2 locus or haplotype analysis might have yielded additional insight into the relationship between genetic variations of the ADRB2 but neither GWAS or
haplotype data were available for all cohorts and we focussed on the SNP rs1042713 since there is a large literature which indicates that this is associated with outcomes for asthma treatment. A fourth limitation is that we have assumed that treatment has been assigned based on the same criteria and it is possible that in some cohorts, children with more severe asthma and at increased risk for exacerbations might not have received LABA treatment but this would tend to underestimate the effect of the interaction between LABA treatment and the SNP rs1042713 for exacerbations. A fifth limitation is that rare variants were not genotyped which could also have an impact on adverse events during LABA therapy; however, these cohorts were not powered for a rare variant analysis and the rare variants identified by Ortega et al \(^{(38)}\) occurred in the background of Gly16, not Arg16. Finally, the polymorphism Gly16Arg allele frequency was not in Hardy-Weinberg Equilibrium for the whole BREATHE cohort but the consistency of the results across the cohorts suggests that the deviation within this single cohort did not substantially influence the overall results. Furthermore, Gly16Arg is an inconsistently replicated and, at best, weak locus for asthma severity so it does not seem plausible that selection for exacerbation (the primary outcome and linked to asthma severity) in this study is the cause for the deviation from HWE seen in the BREATHE cohort. Since Gly16Arg is a better established pharmacogenetic locus, a more plausible outcome which would influence deviations from HWE is exacerbations or symptoms despite frequent SABA use or LABA use, but this represents a small percentage of the BREATHE cohort (18% and 11%, respectively).

In conclusion, children with asthma on ICS plus LABA were at 52% increased risk for exacerbation in the previous 6-12 months for each A allele (Arg16 amino acid) compared to G/G homozygotes (Gly16/Gly16). Knowing that there are 1 million children in the UK with asthma and 10% of these are prescribed LABA \(^{(39)}\) and 60% of these carry at least one Arg16 allele, there are approximately 60,000 children in the UK today, and approximately 25,000 in
the Netherlands, who might be at risk from the morbidity of exacerbation which is preventable by treatment with either no LABA or perhaps with the addition of LTRA if genotyping of rs1042713 could be made available at the point of prescribing. Put another way, and assuming that at least one third of the UK national healthcare costs attributable to childhood asthma are due to urgent care\cite{40,41}, stratified treatment might reduce the annual direct costs to the UK National Health Service for the management of childhood asthma exacerbations by 10% (i.e. a 50% reduction in 60% of the population). Whilst there are no recent published costs for the management of childhood asthma, costs in the US have been estimated at $791 per child per annum in 2005\cite{41} and to total £150 million in the UK in 1997\cite{42}. It is thus likely that stratified treatment in childhood asthma will save tens of millions of pounds in direct healthcare costs. Not all asthmatics who inherit an A allele will experience increased morbidity with LABA treatment and this might be explained by rare variants, perhaps at the same locus\cite{38}, pathway related variation\cite{43}, epigenetic mechanisms or treatment adherence.
REFERENCES


22. Purcell S, Cherny SS, Sham PC. Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003;19:149-50.


Table I. Comparison of details of children in each of the five study populations. *Dutch, Moroccan and Turkish ethnicities were considered Caucasian in PACMAN. †ethnicity data were not available for all participants in PAGES. ‡daily short acting beta agonist status was not determined in GALA II and PASS.¶ minor allele frequency = frequency of minor allele homozygous genotype + (frequency of heterozygous genotype)/2

<table>
<thead>
<tr>
<th></th>
<th>BREATHE n=1210</th>
<th>GALA II n=1171</th>
<th>PACMAN n=760</th>
<th>PAGES n=695</th>
<th>PASS n=390</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% Male (n)</td>
<td>% Exposed to tobacco smoke at home (n)</td>
<td>Mean age, (SD) years</td>
<td>Recent exacerbation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>60% (725)</td>
<td>35% (424)</td>
<td>9.7 (3.8)</td>
<td>44% (536)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>58% (676)</td>
<td>21% (242)</td>
<td>11.9 (2.7)</td>
<td>65% (763)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>63% (478)</td>
<td>14% (108)</td>
<td>8.7 (2.3)</td>
<td>10% (76)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>57% (399)</td>
<td>21% (146)</td>
<td>9.8 (3.7)</td>
<td>47% (323)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>56% (172)</td>
<td>36% (108)</td>
<td>11.1 (4.0)</td>
<td>75% (295)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>% Exposed to tobacco smoke at home (n)</td>
<td>Mean age, (SD) years</td>
<td>Recent exacerbation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0% (n)</td>
<td>15% (n)</td>
<td>44% (n)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>60% (681/753)</td>
<td>90%*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>0.4% (3/753)</td>
<td>93%†</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1%</td>
<td>0%</td>
<td>99% (388/390)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>1%</td>
<td>0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>8.6% (61/753)</td>
<td>0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>7%</td>
<td>0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>1%</td>
<td>0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>2.8% (26/384)</td>
<td>1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>0.37</td>
<td>0.38</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15% (175)</td>
<td>20% (234)</td>
<td>15% (115)</td>
<td>14% (96)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A/A (Arg/Arg) (n)</td>
<td>15% (175)</td>
<td>20% (234)</td>
<td>15% (115)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16% (61)</td>
<td>16% (61)</td>
<td>16% (61)</td>
<td>16% (61)</td>
<td></td>
</tr>
<tr>
<td>rs1042713 genotype</td>
<td>A/G (Arg/Gly) (n)</td>
<td>43% (515)</td>
<td>49% (579)</td>
<td>51% (388)</td>
<td>46% (321)</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td>G/G (Gly/Gly) (n)</td>
<td>43% (520)</td>
<td>31% (358)</td>
<td>34% (257)</td>
<td>40% (278)</td>
</tr>
<tr>
<td>Treatment group</td>
<td>% Short acting beta agonist alone (n)</td>
<td>18% (218)</td>
<td>42% (490)</td>
<td>10% (73)</td>
<td>7% (51)</td>
</tr>
<tr>
<td></td>
<td>% Inhaled corticosteroid, ICS, (n)</td>
<td>58% (698)</td>
<td>24% (283)</td>
<td>63% (476)</td>
<td>40% (273)</td>
</tr>
<tr>
<td></td>
<td>% ICS plus long acting beta agonist, LABA, (n)</td>
<td>11% (138)</td>
<td>10% (122)</td>
<td>19% (147)</td>
<td>19% (134)</td>
</tr>
<tr>
<td></td>
<td>% ICS plus leukotriene receptor antagonist, LTRA, (n)</td>
<td>5% (65)</td>
<td>15% (177)</td>
<td>3% (23)</td>
<td>9% (65)</td>
</tr>
<tr>
<td></td>
<td>% ICS plus LABA plus LTRA, (n)</td>
<td>8% (91)</td>
<td>9% (99)</td>
<td>5% (41)</td>
<td>24% (169)</td>
</tr>
<tr>
<td></td>
<td>% with daily short acting beta agonist dosing, (n)</td>
<td>21% (250)</td>
<td>‡</td>
<td>49% (364)</td>
<td>30% (209)</td>
</tr>
</tbody>
</table>
Table II. Odds ratio for exacerbation per copy of the A allele (Arg16 amino acid). Results are from logistic regression models which adjusted for sex, age and exposure to second hand smoke at home. SABA=short acting beta agonist. ICS =inhaled corticosteroids. LABA= long acting beta agonist. LTRA=leukotriene receptor antagonist. *There were no children in PASS on SABA alone.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>BREATHE Odds ratio [95% confidence interval] for exacerbation per A allele (referenced to none)</th>
<th>GALA II Odds ratio [95% confidence interval] for exacerbation per A allele (referenced to none)</th>
<th>PACMAN Odds ratio [95% confidence interval] for exacerbation per A allele (referenced to none)</th>
<th>PAGES Odds ratio [95% confidence interval] for exacerbation per A allele (referenced to none)</th>
<th>PASS Odds ratio [95% confidence interval] for exacerbation per A allele (referenced to none)</th>
<th>Results from all cohorts combined Odds ratio [95% confidence interval]</th>
<th>Results for all cohorts except GALA II Odds ratio [95% confidence interval]</th>
</tr>
</thead>
<tbody>
<tr>
<td>SABA alone</td>
<td>0.87 [0.54, 1.40] (n=218)</td>
<td>1.08 [0.81, 1.43] (n=490)</td>
<td>1.07 [0.06, 20.2] (n=73)</td>
<td>0.71 [0.18, 2.80] (n=51)</td>
<td>*</td>
<td>1.01 [0.79, 1.28] (n=832) p=0.95</td>
<td>0.85 [0.55, 1.33] (n=342) p=0.49</td>
</tr>
<tr>
<td>ICS alone</td>
<td>1.15 [0.92, 1.43] (n=698)</td>
<td>1.12 [0.78, 1.62] (n=283)</td>
<td>0.83 [0.53, 1.31] (n=476)</td>
<td>1.17 [0.80, 1.71] (n=273)</td>
<td>4.81 [0.79, 29.33] (n=28)</td>
<td>1.11 [0.95, 1.31] (n=1758) p=0.18</td>
<td>1.11 [0.94, 1.33] (n=1475) p=0.22</td>
</tr>
<tr>
<td>ICS+LABA</td>
<td>1.52 [0.92, 2.50] (n=138)</td>
<td>2.07 [1.03, 4.16] (n=122)</td>
<td>2.54 [1.06, 6.06] (n=147)</td>
<td>1.29 [0.76, 2.19] (n=134)</td>
<td>1.21 [0.68, 2.14] (n=96)</td>
<td>1.52 [1.17, 1.99] (n=637) p=0.0021</td>
<td>1.44 [1.08, 1.93] (n=515) p=0.01</td>
</tr>
<tr>
<td>ICS+LTRA</td>
<td>1.86 [0.85, 4.08] (n=65)</td>
<td>1.26 [0.79, 2.02] (n=177)</td>
<td>2.10 [0.43, 10.2] (n=23)</td>
<td>0.69 [0.34, 1.39] (n=65)</td>
<td>0.31 [0.08, 1.18] (n=24)</td>
<td>1.11 [0.80, 1.55] (n=354) p=0.52</td>
<td>0.98 [0.61, 1.56] (n=177) p=0.93</td>
</tr>
<tr>
<td>ICS+LABA+LTRA</td>
<td>1.03 [0.54, 1.96] (n=91)</td>
<td>0.93 [0.36, 2.39] (n=99)</td>
<td>0.23 [0.04, 1.46] (n=41)</td>
<td>0.87 [0.52, 1.45] (n=169)</td>
<td>1.02 [0.70, 1.48] (n=169)</td>
<td>0.94 [0.73, 1.22] (n=569) p=0.65</td>
<td>0.95 [0.72, 1.24] (n=470) p=0.68</td>
</tr>
</tbody>
</table>
Table III. The proportion (percentage) of children with exacerbations stratified by treatment class and SNP rs1042713.

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>BREATHE</th>
<th>GALA II</th>
<th>PACMAN</th>
<th>PAGES</th>
<th>PASS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA</td>
<td>AG</td>
<td>GG</td>
<td>AA</td>
<td>AG</td>
</tr>
<tr>
<td>SABA alone</td>
<td>7/29 (24%)</td>
<td>28/101 (28%)</td>
<td>25/88 (28%)</td>
<td>57/92 (62%)</td>
<td>150/241 (62%)</td>
</tr>
<tr>
<td>ICS alone</td>
<td>52/98 (53%)</td>
<td>121/296 (41%)</td>
<td>126/304 (41%)</td>
<td>43/62 (69%)</td>
<td>93/151 (62%)</td>
</tr>
<tr>
<td>ICS+LABA</td>
<td>18/22 (82%)</td>
<td>25/55 (46%)</td>
<td>33/61 (54%)</td>
<td>25/30 (83%)</td>
<td>43/56 (77%)</td>
</tr>
<tr>
<td>ICS+LTRA</td>
<td>8/11 (73%)</td>
<td>18/26 (69%)</td>
<td>15/28 (54%)</td>
<td>22/34 (65%)</td>
<td>59/81 (73%)</td>
</tr>
<tr>
<td>ICS+LABA+LTRA</td>
<td>11/15 (73%)</td>
<td>23/37 (62%)</td>
<td>26/39 (67%)</td>
<td>13/16 (81%)</td>
<td>37/50 (74%)</td>
</tr>
</tbody>
</table>
Online Repository
METHODS

BREATHE study. This is cohort of children and young adults with doctor diagnosed asthma and was recruited from primary and secondary care in Tayside. Details of enrolment have been presented in detail previously\(^1\). Individuals aged >18 years were excluded from the present analysis.

GALA II study. The genes-environment and admixture in Latino Americans (GALA II) study is a multi-center study of children and young adults with and without asthma, and has been fully described previously\(^2\). Eligibility criteria were: aged 8-21 years of age, all four grandparents were Latino, <10 pack-years of smoking history. Asthma was defined based on physician diagnosis and report of symptoms and medication use within the last 2 years. Individuals aged >18 year and without asthma were excluded from this analysis. Estimates of African, European and Native American ancestries were obtained using an unsupervised analysis in ADMIXTURE\(^3\) assuming 3 ancestral populations: African, European and Native American. We used reference haplotypes from individuals from HapMap phase II (http://hapmap.ncbi.nlm.nih.gov) for the European and African components: Utah residents with Northern and Western European ancestry from the CEPH collection (CEU) and Yoruba in Ibadan, Nigeria (YRI). Native American reference population consisted of 71 Native American individuals genotyped at University of California San Francisco on the Axiom LAT1 array, including 14 Zapotec, 2 Mixe, and 11 Mixtec from the southern State of Oaxaca and 44 Nahua individuals from Central Mexico.

PAGES study. The Paediatric Asthma Gene Environment Study (PAGES, http://www.asthma-pages.com/) was designed to explore interactions between genetic variations and exposures (including medications) in children with asthma. Children were
recruited from primary and secondary care. Details of recruitment have been published earlier \(^4\). Ethnicity was not identified for the initial recruits to the study but was captured for approximately half participants and categorised as African, Chinese, Indian, Mixed, Pakistani, White British or other.

**PACMAN cohort.** The PACMAN study is a study of children aged 4-12 years recruited through community pharmacies in the Netherlands between 2009 and 2012. Details of the study protocol have been described elsewhere\(^5\). A detailed history of the subjects was obtained, including information on asthma symptoms, exacerbations and medication use over the preceding 12 months during a study visit in the community pharmacies. Ethnicity was categorised as African, Asian, Caucasian (Dutch, Turkish or Moroccan), Hispanic or Mixed.

**PASS cohort.** The Pharmaco genetics of Adrenal Suppression with inhaled Steroid study is a cohort study designed to explore the clinical and pharmacogenomics associations between use of corticosteroids in children with asthma and adrenal suppression. Assessment included a respiratory questionnaire, collection of blood or salvia for DNA extraction. Details of recruitment have been published previously\(^6\). Children with an Asian ancestry were excluded and ethnicity for those recruited was categorised as African, Caucasian or other.
Table I. The power of the sample size of the five cohorts combined to detect increases in odds ratio (OR) for asthma exacerbations

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>OR=1.2</th>
<th>OR=1.5</th>
<th>OR=3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short acting beta agonist alone</td>
<td>44%</td>
<td>96%</td>
<td>100%</td>
</tr>
<tr>
<td>Inhaled corticosteroid (ICS)</td>
<td>70%</td>
<td>99%</td>
<td>100%</td>
</tr>
<tr>
<td>ICS plus long acting beta agonist (LABA)</td>
<td>36%</td>
<td>91%</td>
<td>100%</td>
</tr>
<tr>
<td>ICS plus leukotriene receptor antagonist (LTRA)</td>
<td>20%</td>
<td>64%</td>
<td>100%</td>
</tr>
<tr>
<td>ICS plus LABA plus LTRA</td>
<td>34%</td>
<td>89%</td>
<td>100%</td>
</tr>
</tbody>
</table>
Table II. Odds ratio for exacerbation regardless of treatment in each cohort from the additive model. The odds ratio indicates the risk for each A allele of rs1042713. The logistic regression models adjusted for age, sex and exposure to cigarette smoke. The p value for the pooled analysis was 0.035.

<table>
<thead>
<tr>
<th></th>
<th>BREATHE</th>
<th>GALA II</th>
<th>PACMAN</th>
<th>PAGES</th>
<th>PASS</th>
<th>POOLED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odds ratio [95% CI]</td>
<td>1.14 [0.97, 1.34]</td>
<td>1.18 [0.98, 1.41]</td>
<td>1.00 [0.69, 1.41]</td>
<td>1.02 [0.82, 1.28]</td>
<td>1.08 [0.81, 1.43]</td>
<td><strong>1.11 [1.01, 1.22]</strong></td>
</tr>
<tr>
<td>n</td>
<td>1210</td>
<td>1171</td>
<td>760</td>
<td>695</td>
<td>390</td>
<td></td>
</tr>
</tbody>
</table>
Table III. Odds ratio (OR) and 95% confidence interval [CI] for exacerbation for each Arg16 allele compared to Gly16 homozygotes among children in receipt of daily short acting beta agonist (SABA) use regardless of other treatment. The logistic regression models adjusted for sex, age and exposure to cigarette smoke. The p value for the pooled analysis was 0.91.

<table>
<thead>
<tr>
<th></th>
<th>BREATHE</th>
<th>PACMAN</th>
<th>PAGES</th>
<th>POOLED</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR [95% CI] for children in receipt of SABA every day</td>
<td>1.13 [0.77, 1.65] n=250</td>
<td>1.41 [0.83, 2.40] n=364</td>
<td>0.69 [0.44, 1.10] n=208</td>
<td><strong>1.01 [0.79, 1.31]</strong></td>
</tr>
</tbody>
</table>


Table IV. Odds ratio (OR) and 95% confidence interval [CI] for exacerbation using the additive model (i.e. risk for each Arg16 allele compared to none) among children treated with inhaled corticosteroids and long acting beta agonists for the three populations where short acting beta agonist (SABA) use was determined. The logistic regression models adjusted for sex, age and exposure to cigarette smoke. The p values for the pooled analysis were 0.22 and 0.038.

<table>
<thead>
<tr>
<th></th>
<th>BREATHE</th>
<th>PACMAN</th>
<th>PAGES</th>
<th>POOLED</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OR [95% CI] for children in</strong></td>
<td><strong>BREATHE</strong></td>
<td><strong>PACMAN</strong></td>
<td><strong>PAGES</strong></td>
<td><strong>POOLED</strong></td>
</tr>
<tr>
<td><strong>receipt of SABA every day</strong></td>
<td>1.02 [0.37, 2.81]</td>
<td>4.57 [1.40, 14.89]</td>
<td>0.89 [0.30, 2.63]</td>
<td>1.49 [0.79, 2.79]</td>
</tr>
<tr>
<td><strong>n=44</strong></td>
<td><strong>n=74</strong></td>
<td><strong>n=47</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OR [95% CI] for children in</strong></td>
<td><strong>BREATHE</strong></td>
<td><strong>PACMAN</strong></td>
<td><strong>PAGES</strong></td>
<td><strong>POOLED</strong></td>
</tr>
<tr>
<td><strong>receipt of SABA less than once a</strong></td>
<td>1.71 [0.94, 3.12]</td>
<td>0.65 [0.06, 19.51]</td>
<td>1.55 [0.80, 2.99]</td>
<td>1.59 [1.03, 2.45]</td>
</tr>
<tr>
<td><strong>day</strong></td>
<td><strong>n=94</strong></td>
<td><strong>n=72</strong></td>
<td><strong>n=87</strong></td>
<td></td>
</tr>
</tbody>
</table>
REFERENCES


